MCID: CYT019
MIFTS: 33

Cytogenetically Normal Acute Myeloid Leukemia

Categories: Cancer diseases

Aliases & Classifications for Cytogenetically Normal Acute Myeloid Leukemia

MalaCards integrated aliases for Cytogenetically Normal Acute Myeloid Leukemia:

Name: Cytogenetically Normal Acute Myeloid Leukemia 25 69
Acute Myelogenous Leukemia with Normal Karyotype 25
Normal Karyotype Acute Myeloid Leukemia 25
Cn-Aml 25
Nk-Aml 25

Classifications:



Summaries for Cytogenetically Normal Acute Myeloid Leukemia

Genetics Home Reference : 25 Cytogenetically normal acute myeloid leukemia (CN-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and cell fragments called platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary : Cytogenetically Normal Acute Myeloid Leukemia, also known as acute myelogenous leukemia with normal karyotype, is related to leukemia and myeloid leukemia. An important gene associated with Cytogenetically Normal Acute Myeloid Leukemia is FLT3 (Fms Related Tyrosine Kinase 3), and among its related pathways/superpathways are Glucose / Energy Metabolism and Peroxisome. The drugs Cytarabine and ponatinib have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and growth/size/body region

Related Diseases for Cytogenetically Normal Acute Myeloid Leukemia

Diseases related to Cytogenetically Normal Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
id Related Disease Score Top Affiliating Genes
1 leukemia 10.8
2 myeloid leukemia 10.8
3 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 10.5 FLT3 NPM1
4 acute myeloid leukemia with recurrent genetic anomaly 10.5 FLT3 NPM1
5 central nervous system mature teratoma 10.4 FLT3 NPM1
6 acute necrotizing encephalopathy 10.4 FLT3 KMT2A
7 alopecia antibody deficiency 10.3 FLT3 WT1
8 pulmonary valve agenesis-tetralogy of fallot-absence of ductus arteriosus syndrome 10.3 CEBPA FLT3
9 aneurysm, intracranial berry, 1 10.1 KMT2A NPM1
10 adult acute lymphocytic leukemia 10.1 FLT3 KMT2A
11 mn1 10.1
12 cholesteatoma 10.0 FLT3 KMT2A NPM1
13 preeclampsia/eclampsia 3 10.0 FLT3 KMT2A
14 spinocerebellar ataxia, autosomal recessive 21 10.0 FLT3 KMT2A NPM1
15 optic disk drusen 9.9 IDH1 IDH2
16 nemaline myopathy 9.9 IDH1 IDH2
17 endolymphatic sac tumor 9.9 IDH1 IDH2
18 mixed oligodendroglioma-astrocytoma 9.9 IDH1 IDH2
19 congenital disorder of glycosylation, type if 9.9 IDH1 IDH2
20 anca-associated vasculitis 9.9 IDH1 IDH2
21 bone osteosarcoma 9.9 IDH1 IDH2
22 breast papillomatosis 9.9 IDH1 IDH2
23 peroxisome biogenesis disorder 5a 9.9 FLT3 KMT2A WT1
24 early myoclonic encephalopathy 9.9 IDH1 IDH2
25 neurotic disorder 9.8 IDH1 IDH2
26 juxtacortical chondrosarcoma 9.8 IDH1 IDH2
27 schwannoma of jugular foramen 9.8 IDH1 IDH2
28 myelodysplastic syndrome 9.8
29 acute leukemia 9.8
30 hematopoietic stem cell transplantation 9.8
31 allergic hypersensitivity disease 9.8 IDH1 IDH2
32 vascular cancer 9.8 IDH1 IDH2
33 achard syndrome 9.8 IDH1 IDH2
34 dyserythropoietic anemia and thrombocytopenia 9.8 CEBPA FLT3 WT1
35 brachydactyly 9.7 IDH1 IDH2
36 fallopian tube papillary adenocarcinoma 9.7 IDH1 IDH2
37 peritoneal serous adenocarcinoma 9.7 IDH1 IDH2
38 fryns macrocephaly 9.7 IDH1 IDH2
39 systemic lupus erythematosus 2 9.6 IDH1 IDH2
40 hemolytic anemia 9.5 FLT3 KMT2A NPM1 WT1
41 cri-du-chat syndrome 9.5 IDH1 IDH2 NPM1
42 spinal cord glioma 9.5 IDH1 IDH2
43 leukemia, acute myeloid 9.5 FLT3 KMT2A NPM1 WT1
44 liver cirrhosis 9.3 CEBPA FLT3 NPM1
45 cheek mucosa cancer 9.3 CEBPA FLT3 NPM1 WT1
46 acute lymphoblastic leukemia, childhood 9.3 CEBPA FLT3 KMT2A WT1
47 apocrine adenocarcinoma 9.2 IDH1 IDH2
48 acute pre-b-cell lymphoblastic leukemia 8.5 CEBPA FLT3 IDH1 IDH2 NPM1
49 essential pentosuria 7.5 CEBPA FLT3 IDH1 IDH2 KMT2A NPM1
50 cranioectodermal dysplasia 1 7.5 CEBPA FLT3 IDH1 IDH2 KMT2A NPM1

Graphical network of the top 20 diseases related to Cytogenetically Normal Acute Myeloid Leukemia:



Diseases related to Cytogenetically Normal Acute Myeloid Leukemia

Symptoms & Phenotypes for Cytogenetically Normal Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.7 FLT3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.7 FLT3 WT1 CEBPA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.7 CEBPA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.7 FLT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.7 FLT3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 9.7 FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.7 CEBPA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.7 CEBPA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.7 CEBPA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.68 WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.68 FLT3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.68 FLT3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.68 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.68 FLT3 CEBPA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.68 FLT3 WT1 CEBPA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.68 FLT3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.68 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.68 FLT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.68 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.68 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.68 FLT3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.68 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.68 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.68 WT1 CEBPA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.68 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.68 FLT3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.68 WT1 CEBPA

MGI Mouse Phenotypes related to Cytogenetically Normal Acute Myeloid Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.85 FLT3 IDH1 KMT2A NPM1 CEBPA WT1
2 cardiovascular system MP:0005385 9.8 IDH2 KMT2A NPM1 CEBPA WT1
3 hematopoietic system MP:0005397 9.8 FLT3 IDH1 KMT2A NPM1 CEBPA WT1
4 immune system MP:0005387 9.73 FLT3 IDH1 KMT2A NPM1 CEBPA WT1
5 liver/biliary system MP:0005370 9.46 KMT2A NPM1 CEBPA WT1
6 neoplasm MP:0002006 9.43 IDH2 KMT2A NPM1 CEBPA WT1 FLT3
7 no phenotypic analysis MP:0003012 8.92 FLT3 KMT2A CEBPA WT1

Drugs & Therapeutics for Cytogenetically Normal Acute Myeloid Leukemia

Drugs for Cytogenetically Normal Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
2
ponatinib Approved Phase 1, Phase 2 943319-70-8 24826799
3 Anti-Infective Agents Phase 1, Phase 2
4 Antimetabolites Phase 1, Phase 2
5 Antimetabolites, Antineoplastic Phase 1, Phase 2
6 Antiviral Agents Phase 1, Phase 2
7 Immunosuppressive Agents Phase 1, Phase 2
8 PONATINIB  Phase 1, Phase 2
9 Protein Kinase Inhibitors Phase 1, Phase 2

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Ponatinib for FLT3-ITD Acute Myelogenous Leukemia Recruiting NCT02428543 Phase 1, Phase 2 Ponatinib and Cytarabine

Search NIH Clinical Center for Cytogenetically Normal Acute Myeloid Leukemia

Genetic Tests for Cytogenetically Normal Acute Myeloid Leukemia

Anatomical Context for Cytogenetically Normal Acute Myeloid Leukemia

MalaCards organs/tissues related to Cytogenetically Normal Acute Myeloid Leukemia:

39
Myeloid, Bone, Bone Marrow

Publications for Cytogenetically Normal Acute Myeloid Leukemia

Articles related to Cytogenetically Normal Acute Myeloid Leukemia:

(show top 50) (show all 88)
id Title Authors Year
1
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. ( 28473620 )
2017
2
E-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis. ( 28584213 )
2017
3
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. ( 28679652 )
2017
4
Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. ( 28882949 )
2017
5
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. ( 28340577 )
2017
6
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. ( 28076884 )
2017
7
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. ( 28407515 )
2017
8
A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia. ( 28473658 )
2017
9
Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia. ( 28443469 )
2017
10
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia. ( 28197208 )
2017
11
The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. ( 27003236 )
2016
12
Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission. ( 27626217 )
2016
13
Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia. ( 27903973 )
2016
14
The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia - Response to Rashidi etA al. ( 27090743 )
2016
15
High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. ( 27686215 )
2016
16
High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia. ( 26910834 )
2016
17
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia. ( 27884166 )
2016
18
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia. ( 25924238 )
2015
19
Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics. ( 26526573 )
2015
20
High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia. ( 25779662 )
2015
21
Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. ( 26066811 )
2015
22
Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia. ( 26177509 )
2015
23
Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. ( 25646775 )
2015
24
Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. ( 26189213 )
2015
25
Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia. ( 26506237 )
2015
26
Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. ( 26590764 )
2015
27
Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. ( 26317398 )
2015
28
High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. ( 25523507 )
2014
29
A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes. ( 25030037 )
2014
30
Wilms tumor 1 gene mutations in patients with cytogenetically normal acute myeloid leukemia. ( 25035671 )
2014
31
High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. ( 25441683 )
2014
32
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. ( 24413067 )
2014
33
Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. ( 23540998 )
2014
34
TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. ( 24898826 )
2014
35
NPM1 gene mutation in Egyptian patients with cytogenetically normal acute myeloid leukemia. ( 25648021 )
2014
36
Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. ( 23647058 )
2014
37
Cytogenetically Normal Acute Myeloid Leukemia with a Novel KIT Mutation in Exon 11 G565V Developing a Sole Trisomy 13 at Relapse: A Clinical Dilemma. ( 24968822 )
2014
38
DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome. ( 24512939 )
2014
39
Prognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemia. ( 25435718 )
2014
40
Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. ( 24737308 )
2014
41
Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers. ( 24717571 )
2014
42
TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations. ( 24859829 )
2014
43
Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. ( 24711548 )
2014
44
Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. ( 25552703 )
2014
45
Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia. ( 23592435 )
2013
46
Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. ( 24301914 )
2013
47
Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. ( 23150981 )
2013
48
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. ( 23765227 )
2013
49
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. ( 23650424 )
2013
50
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. ( 23020761 )
2013

Variations for Cytogenetically Normal Acute Myeloid Leukemia

Expression for Cytogenetically Normal Acute Myeloid Leukemia

Search GEO for disease gene expression data for Cytogenetically Normal Acute Myeloid Leukemia.

Pathways for Cytogenetically Normal Acute Myeloid Leukemia

Pathways related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.8 CEBPA IDH1 IDH2
2 11.24 IDH1 IDH2
3 11.18 CEBPA FLT3 KMT2A WT1
4 11.07 FLT3 IDH1
5
Show member pathways
10.07 IDH1 IDH2

GO Terms for Cytogenetically Normal Acute Myeloid Leukemia

Biological processes related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.71 CEBPA KMT2A NPM1 WT1
2 positive regulation of transcription, DNA-templated GO:0045893 9.62 CEBPA KMT2A NPM1 WT1
3 negative regulation of cell proliferation GO:0008285 9.46 CEBPA KMT2A NPM1 WT1
4 mitochondrion organization GO:0007005 9.43 CEBPA IDH2
5 tricarboxylic acid cycle GO:0006099 9.37 IDH1 IDH2
6 2-oxoglutarate metabolic process GO:0006103 9.26 IDH1 IDH2
7 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
8 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.55 CEBPA FLT3 IDH1 KMT2A NPM1
2 transcription regulatory region DNA binding GO:0044212 9.43 CEBPA KMT2A WT1
3 NAD binding GO:0051287 9.37 IDH1 IDH2
4 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.32 IDH1 IDH2
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
6 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Cytogenetically Normal Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....